BioGaia_®

BioGaia signs exclusive agreement in Egypt

BioGaia has signed an agreement with Minapharm Pharmaceuticals for the exclusive rights to sell BioGaia Protectis drops in Egypt. The probiotic will be sold under the BioGaia brand. Launch is planned to Q4 2021.

Minapharm is a leading pharmaceutical company in Egypt and the Middle East and the premier biopharmaceutical company in the region. Minapharm develops, manufactures and commercialises medicines ranging from small molecules to complex genetically engineered proteins, as well as develops and licenses advanced technologies in the field of proteins and also cell and gene therapy to global pharma players. Headquartered in Cairo, the company commercialises over 100 products. With a workforce of over 1,400 employees, Minapharm has established an integrated business model composed of international and regional subsidiaries.

"This agreement coincides with Minapharm's expansion programme towards nutritional supplements. BioGaia is a world leader in probiotics and hence, a perfect fit to our broad gastroenterology portfolio in a high demand region," says Dr. Wafik Bardissi, Chairman and CEO of Minapharm Pharmaceuticals.

"I am very happy to be able to extend our coverage in Africa by entering Egypt with a regional and professional partner," says Isabelle Ducellier, CEO of BioGaia.

For additional information please contact Isabelle Ducellier, CEO, telephone: +46 8 555 293 00

Latest press releases from BioGaia

07.04.2021	Notice to attend the Annual General Meeting of BioGaia AB (publ)
31.03.2021	BioGaia publishes annual report for 2020
17.03.2021	BioGaia Invest (BGI) – a new subsidiary focusing on innovative investments to support the growth of BioGaia

BioGaia is a Swedish world-leading probiotic company that has been at the forefront of microbiome research for more than 30 years. BioGaia develops, markets and sells probiotic products with documented health benefits. To date, over 200 articles on clinical trials with BioGaia's probiotic strains have been published. The products are sold by nutrition and pharmaceutical companies in more than 100 countries. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. <u>biogaia.com</u>